DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

Information source: University of Utah
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Herpes Labialis

Intervention: valacyclovir+clobetasol gel (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: University of Utah

Official(s) and/or principal investigator(s):
Christopher Hull, MD, Principal Investigator, Affiliation: University of Utah

Summary

A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).

Clinical Details

Official title: Valacyclovir+Temovate Gel for the Episodic Treatment of Herpes Labialis: A Patient-Initiated Double-Blind, Placebo-Controlled Study, Randomized Study.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: The primary efficacy variable is the maximum size of the primary lesion complex

Secondary outcome: Secondary variables include: the proportion of primary lesions that are aborted; the mean time to healing of the primary lesion complex the frequency and mean duration of lesion pain among primary lesions; the frequency of secondary lesions

Detailed description: Herpes simplex labialis is a common, worldwide affliction for which neither public health procedures, vaccines, nor antiviral chemotherapy have had a major impact. The present study has been proposed because it has become clear there are marked limitations to the benefit of antiviral therapy in herpes labialis. Recently, a pilot trial of the combination of famciclovir and topical 0. 05% fluocinonide vs famciclovir alone showed that the addition of corticosteroids to the antiviral drug treatment caused a marked and statistically significant reduction in lesion size and a trend to more aborted lesions. This study is designed as a randomized, placebo-controlled, , patient-initiated study. The objective of this study is to evaluate the safety and efficacy of oral valacyclovir 2grams BID for one day and topical temovate 0. 05% gel BID for three days compared to placebo capsules and placebo gel in the episodic treatment of a single episode of recurrent herpes labialis in immunologically normal patients. Subjects will be screened, randomized to study drug and instructed to start using study drug within one hour of the first sign or symptom of their next episode of herpes labialis. Data on the treated lesion will be collected by clinic visits and a patient diary card.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age 18 years or older.

- A history typical for recurrent herpes labialis. The subject must have experienced

three or more cold sores in the last 12 months.

- In general good health, without other serious medical conditions, as determined by

the patient's account of his/her medical history.

- Signature on the informed consent document.

Exclusion Criteria:

- Patients who have participated in an investigational drug study in the four-week

period prior to enrollment.

- Previous herpes vaccine at any time.

- Patients with major medical conditions such as chronic heart, pulmonary, renal or

hepatic diseases.

- Patients with immunodeficiency disorders such as HIV infection or cancer

chemotherapy.

- Patients using topical steroids on or near the face or systemic steroids within 30

days of enrollment.

- Women who are pregnant, lactating or breast feeding.

- Women of childbearing potential not using adequate contraception as judged by the

Investigator.

- Recent history of alcohol or drug abuse, which in the opinion of the investigator,

may interfere with that study patient's compliance with study requirements.

- Significant skin disease such as atopic dermatitis, acne, or rosacea that would

interfere with the assessment of lesions.

- Allergy or hypersensitivity to steroids, acyclovir, penciclovir and/or other

nucleoside analogues.

- Subjects with impaired renal function as defined as a serum creatinine above the

upper limits of normal.

Locations and Contacts

University of Utah, Salt Lake City, Utah 84132, United States
Additional Information

Starting date: September 2004
Last updated: April 30, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017